Mounjaro: what to expect week by week, from first dose to real results

What the trial data tells us about the pace of weight loss

The SURMOUNT-1 results are striking, but they describe 72 weeks, nearly a year and a half. That timescale matters. Most participants lost weight steadily across the whole period rather than rapidly in the first few months. The plateau that many people associate with long-term dieting was significantly blunted: tirzepatide continued driving loss well into the second year for many participants.

Earlier in the programme, at around 16–20 weeks, a meaningful reduction was already visible for most participants, typically in the range of 5–10% of starting weight. This aligns with NICE's appraisal of tirzepatide (TA1026), which sets a clinical checkpoint: if less than 5% weight loss has occurred after six months at the highest tolerated dose, the prescriber will review whether continuing makes sense.

The practical implication is straightforward. If you are in week three and the scales have barely moved, that is not failure, it is the expected shape of the early phase. The 2.5 mg starting dose is designed to settle your system; therapeutic appetite suppression builds as the dose increases. Expecting the trial's headline figure to arrive in the first fortnight sets you up for unnecessary frustration. Our page on what to expect from tirzepatide across the full course of treatment can help calibrate those early expectations, and reading about what to expect from Mounjaro across the full course of treatment can help calibrate those early expectations.

Weight loss is also rarely linear. A week of no change followed by a noticeable drop the following week is entirely normal. Hormonal cycles, water retention from starting a new exercise habit, and variation in what you eat can all produce apparent stalls that resolve without any change to treatment.

The first four weeks: adjustment before appetite change

For most people, what to expect in the first week on Mounjaro is not dramatic appetite suppression but a period of adjustment. Nausea is the most commonly reported early side effect, usually mild, often peaking a day or two after injection, and settling within the first week or two for most users. Constipation, loose stools, burping and a general sense of fullness after very small amounts of food are also typical in this window.

These effects reflect the medicine working as intended: gastric emptying slows, gut hormones shift, and your digestive system recalibrates. The NHS tirzepatide medicine page lists the full side-effect profile and describes what most people can expect at each stage. Most people find that sipping water steadily through the day, eating smaller portions more slowly, and avoiding very fatty or spicy meals in the first few days after each injection keeps symptoms manageable.

A smaller number of people feel almost nothing in week one, no nausea, no obvious appetite change. That is also normal at 2.5 mg. What to expect in the first week on Mounjaro is genuinely variable; the absence of side effects is not a sign the medicine is not working.

After the first four weeks, most people move to 5 mg. For many, this is when appetite suppression becomes more obvious, the sense that a normal portion is simply enough, sometimes before it is finished. That shift in hunger cues, rather than willpower, is the mechanism that drives the trial results.

Months two to six: where most of the noticeable change happens

The phase between roughly six weeks and six months is, for most people, when Mounjaro's effect becomes genuinely visible. Appetite reduction is more consistent, energy intake falls without the sense of deprivation that accompanies calorie restriction alone, and weight loss becomes more predictable week on week. This is also the period when dose increases typically occur, moving through 7.5 mg and potentially 10 mg under prescriber guidance.

Side effects that were prominent at 2.5 mg often settle considerably by this stage, though some people experience a milder recurrence with each dose step. Fatigue, occasional headaches and dizziness can appear alongside the GI effects, and are usually short-lived. The important things to watch for (and seek medical help for promptly) are severe or persistent stomach pain, particularly any that radiates to the back (which can indicate pancreatitis), and signs of dehydration if vomiting or diarrhoea is sustained.

For a closer look at how the second month in particular tends to unfold, our page on what to expect in week two covers the early transition in more detail. And for those considering how long people typically stay on Mounjaro, the current guidance is that most people benefit from continued use beyond six months if progress is on track.

This is also the phase where the lifestyle elements matter most. Mounjaro reduces appetite; it does not independently protect muscle mass or ensure good nutrition. Adequate protein, hydration and regular activity (even walking) make a material difference to both results and how you feel day to day. Our prescribers can point you toward practical guidance as part of aftercare.

Receiving your treatment and what happens at each review

When treatment is approved, your pen is dispatched the same day if your consultation is completed before 12pm Monday to Friday. It arrives the next working day via DPD, in plain unbranded packaging, no indication of contents on the outside. Inside is the Mounjaro KwikPen: a pre-filled device containing four weekly doses, stored in the fridge between uses.

Each repeat order at nume involves a clinical review before dispatch. That means your prescriber looks at how you are progressing, what dose you are on, and whether any changes are appropriate, not a rubber stamp, but a proper check. Cost context for private treatment is something many people want to understand before starting; the Mounjaro cost and pricing page covers what the UK market typically looks like and what a legitimate price includes.

If you are ready to talk through whether Mounjaro is right for your situation, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not an automated system.